Wave Life Sciences Stock Surges On Promising Interim Data From …
WEB8 hours ago · On Tuesday, Wave Life Sciences Ltd. (NASDAQ:WVE) revealed interim data from the ongoing Phase 2 FORWARD-53 study of WVE-N531 for Duchenne muscular dystrophy (DMD) patients amenable to exon 53 ...
Wave Life Sciences Announces Positive Interim Data from …
WEB23 hours ago · CAMBRIDGE, Mass., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced positive interim data from the ongoing Phase 2 FORWARD-53 study of WVE …
Wave Life Sciences’ stock soars 51% after biotech posts positive …
WEB5 hours ago · The stock of small-cap biotech Wave Life Sciences Inc. soared 51% Tuesday after the company reported positive interim data from a mid-stage trial of a treatment for the rare muscle disorder ...
Wave surfs DMD success to regulators' doors, sending stock up
WEB9 hours ago · The biotech expects to report 48-week data in the first quarter of 2025. Feedback from regulators on a pathway to accelerated approval are due around the same time. Shares in Wave opened up 39% at ...
Wave Life Sciences Announces Proposed Public Offering of
WEB3 hours ago · Follow. CAMBRIDGE, Mass., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines ...
Wave Life Sciences: Spiking On Strong DMD Data, But Not Fully …
WEB3 hours ago · Wave Life Sciences stock surged over 50% today due to promising data from its Duchenne Muscular Dystrophy candidate WVE-N531, showing >5% dystrophin production. The safety profile of WVE-N531 is ...
Wave Life Sciences Reports Positive Data From Phase 2 …
WEB11 hours ago · (RTTNews) - Wave Life Sciences Ltd. (WVE), a clinical-stage biotechnology company, Tuesday announced positive interim data from the Phase 2 FORWARD-53 study evaluating WVE-N531 in boys with ...
Press Releases - Wave Life Sciences
WEBMay 7, 2024 · Wave Life Sciences Announces Positive Results from Phase 1b/2a SELECT-HD Trial with First Clinical Demonstration of Allele-Selective Mutant Huntingtin Lowering in Huntington’s Disease
Wave Life Sciences
WEBMay 7, 2024 · We are advancing a pipeline of first- or best-in-class therapeutics with life-changing potential, including in Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington’s disease, and obesity.
Wave Life Sciences and GSK Announce Collaboration to Drive …
WEBDec 13, 2022 · Wave will lead all preclinical research for GSK and Wave programs up to investigational new drug (IND) enabling studies. GSK collaboration programs will transfer to GSK for IND-enabling studies, clinical development, and commercialization.